ANUH PHARMA LTD.

CIN: L24230MH1960PLC011586

Regd. Office: 3-A, North Wing, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai - 400018
Tel: +91 22 6622 7575; Fax: +91 22 6622 7600; Email: anuh@sk1932.com; Website: www.anuhpharma.com
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30th SEPTEBER, 2020

Sr. No.	Particulars	3 months ended 30/09/2020	3 months ended 30/06/2020	3 months ended 30/09/2019	6 months ended 30/09/2020	6 months ended 30/09/2019	12 months ended 31/03/2020
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)
I.	Revenue from operations	11,223.54	12,424.77	7,415.46	23,648.31	15,904.89	30,695.96
II.	Other income	336.88	309.64	83.26	646.52	208.90	421.23
III.	Total Revenue (I + II)	11,560.42	12,734.41	7,498.72	24,294.83	16,113.79	31,117.19
IV.	Expenses:						
	Cost of materials consumed	9,438.89	6,676.20	5,763.85	16,115.09	11,653.45	23,965.58
	Purchases of Stock-in-Trade	1.38	173.75	268.63	175.13	358.47	401.45
	Changes in inventories of finished goods, work-in- progress and Stock-in-Trade	(938.24)	1,753.09	(331.11)	814.85	332.97	(1,350.76)
	Employee benefits expense	386.86	344.29	321.11	731.15	633.49	1,336.23
	Finance costs	47.79	44.80	5.71	92.59	13.64	79.22
	Depreciation and amortization expense	372.94	373.04	101.05	745.98	193.03	703.26
	Other expenses	1,261.80	1,139.08	934.95	2,400.88	1,696.63	4,066.65
	Total expenses (IV)	10,571.42	10,504.25	7,064.19	21,075.67	14,881.68	29,201.63
V	Profit / (Loss) before exceptional and items and tax (III - IV)	989.00	2,230.16	434.53	3,219.16	1,232.11	1,915.56
VI.	Exceptional items	-				H-	
VII.	Profit / (Loss) before tax (V - VI)	989.00	2,230.16	434.53	3,219.16	1,232.11	1,915.56
VIII	Tax expense:						
	(1) Current tax	308.00	549.00	139.00	857.00	353.00	370.00
	(2) Deferred tax	17.17	9.06	(5.42)	26.23	(9.21)	130.70
	(3) MAT Credit Entitlement		-	- 100 50		2.42.770	(15.67)
		325.17	558.06	133.58	883.23	343.79	485.03
IX	Profit/(Loss) after Tax (VII-VIII)	663.83	1,672.10	300.95	2,335.93	888.32	1,430.53
X	Other Comprehensive Income (net of Tax)						
	(i) Items that will not be reclassified to profit or loss	(16.28)	10.59	(0.52)	(5.69)	(8.13)	(9.22)
	(ii) Items that will be reclassified to profit or loss	- (-	-	-	- 1	-
	Total Other Comprehensive Income (net of Tax)	(16.28)	10.59	(0.52)	(5.69)	(8.13)	(9.22)
XI	Total Comprehensive Income for the period (IX + X) (Comprising Profit / (Loss) and Other	647.55	1,682.69	300.43	2,330.24	880.19	1,421.31
	Comprehensive Income for the period) Paid up Equity Share Capital (Face value Rs. 5/- each)	2,505.60	1,252.80	1,252.80	2,505.60	1,252.80	1,252.80
	Other Equity (excluding revaluation reserves)						14,967.94
XII	Earnings per equity share (Non annualised) (In Rs.) (Refer note no.3)						
	(1) Basic	1.32	3,34	0.60	4.66	1.77	2.85
	(1) Dasic			 	4.66		



(Rs. in Lakhs)

			(Rs. in Lakhs)	
	PARTICULARS	As at September 30, 2020	As at March 31, 2020	
		Unaudited	Audited	
I	ASSETS			
1	Non-current Assets			
	(a) Fixed Assets			
J	(i) Property, Plant and equipment	7,772.44	8,318.77	
ļ	(ii) Capital work-in-progress	37.77	0,5,0,,,	
		28.44	28.90	
	(iii) Intangible Assets	1	l	
J	(iv) Right of use assets	28.19	56.62	
		7,866.84	8,404.29	
	(b) Financial Assets			
	(i) Investments	1,721.62	1,369.52	
ĺ	(ii) Other Financial Assets	149.58	399.68	
	(11)			
ŀ	(c) Income Tax Assets		126.84	
	(c) Income Tax Assets	_	120.04	
ĺ		* * * * **	41.61	
	(d) Other Non Current Assets	14.17	41.61	
	Total Non-Current Assets	9,752.21	10,341.94	
2	Current Assets			
	(a) Inventories	5,154.51	6,148.75	
	(4)	,	'	
	(b) Financial Assets			
	1 ` '	7.0(1.02	(596 24	
	(i) Investments	7,861.83	6,586.24	
	(ii) Trade receivables	11,787.55	8,103.12	
	(iii) Cash and cash equivalents	450.61	184.52	
	(iv) Other Bank balances	321.31	67.29	
	(v) Loans and Advances	94.96	112.71	
	(vi) Other financial assets	396.98	226.89	
	(c) Other current assets	557.09	865.97	
			22,295.49	
	Total Current Assets	26,624.84		
	TOTAL ASSE	TS 36,377.05	32,637.43	
I	EQUITY AND LIABILITIES			
	Equity			
	(i) Equity Share Capital	2,505.60	1,252.80	
	(ii) Other Equity	16,045.36	14,967.94	
	TOTAL EQUITY	18,550.96	16,220.74	
	Liabilities	10,550,50		
1	NON-CURRENT LIABLITIES		7 77	
	(i) Lease Liabilities	1	7.77	
	(ii) Provisions	129.43	117.29	
	(iii) Deferred Tax Liabilities(Net)	44.62	20.73	
	TOTAL NON-CURRENT LIABLITIES	174.05	145.79	
			[
2	CURRENT LIABLITIES			
_	(a) Financial Liaiblities			
	(i) Borrowings	5,373.50	4,456.00	
	• • •	i '	51.69	
	(ii) Lease Liabilities	30.33	31.09	
	(iii) Trade Payables:			
	Due to Micro and Small Enterprises	187.86	50.60	
	Due to other than Micro and Small Enterprises	10,720.17	10,413.27	
	(iv) Other financial liabilities	982.20	800.02	
	• • • • • • • • • • • • • • • • • • • •			
	(b) Other current liabilities	89.61	479.41	
	• •	20.36	19.91	
	(c) Provisions	i	19.91	
	(d) Current Tax Liabilities(Net)	248.01		
	TOTAL CURRENT LIABLITIES	17,652.04	16,270.90	
	TOTAL EQUITY AND LIABILIT	TES 36,377.05	32,637.43	
	·			

marah

CASH FLOW STATEMENT

	Particulars		Period ended on September 30,		Period ended on September 30, 2019	
······································		2020 Unaudited		2019 Unaudited		
A)	CASH FLOW FROM OPERATING ACTIVITIES:	Ona	uncu			
	NET PROFIT BEFORE TAX		3,219.16		1,232.1	
	Adjustment for:		,		•	
	Depreciation and Amortization	745.98		193.03		
I	Finance Costs	92.59		13.64		
	Interest Income	(19.73)		(20.52)		
	Market to Market (gain) / loss on investment	188.47		141.99		
	Market to Market (gain) / loss on Derivative	-		2.11		
	Provision for Gratuity & Leave Encashment	17.54		12.48		
Į.	Provision for Doubtful Debts	25.60		7.66		
	Dividend Income	(76.76)		(104.29)		
	Loss/(Profit) on Sale of fixed assets	3.00		(0.02)		
	Loss/(Profit) on Sale of Investment	(547.08)		(82.73)		
			429.61	<u> </u>	163.3	
ĺ	OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES		3,648.77		1,395.	
	Adjustment for:					
	Trade and Other Receivables	(3,710.01)		(137.37)		
	Inventories	994.24		687.22		
-	Other Financial Assets	(167.00)		18.66		
	Loans and Advances	17.75		(36.80)		
- 1	Other Current Assets	308.88		285,95		
- 1	Trade Payables	444.16		1,244.88		
- 1	Other Financial Liabilities	380.47		179.55		
	Other current Liabilities	(389.80)		(62.81)		
ł	Gratuity & Leave Encashment paid	(13.85)		(28.88)		
-	,		(2,135.16)		2,150.	
	CASH GENERATED FROM OPERATIONS		1,513.61		3,545.8	
	Direct Taxes paid	(482.14)	(482.14)	(290.66)	(290.	
	NET CASH FROM OPERATIONS	(102121)	1,031.47	(3,255.	
	CASH FLOW FROM INVESTING ACTIVITIES:					
	(Purchase)/Sale of Investments [net]	(1,269.07)		(1,269.28)		
	Purchase of Property, Plant and Equipment and Capital Work in Progress	(375.75)		(2,363.18)		
- 1	Sale of Property, Plant and Equipment	6.45		1.20		
	Interest Income	12.72		14.07		
-	Dividend Income	76.76		104.29		
	NET CASH USED IN INVESTING ACTIVITIES		(1,548.89)		(3,512.	
	CASH FLOW FROM FINANCING ACTIVITIES:					
	Total proceeds from Borrowings (net of repayments):					
	Secured Loans/Short Term Borrowings	917.50		601.46		
	Payment of Lease Liabilities	(31.41)		(39.11)		
	Finance Costs	(106.60)		(8.67)		
	Dividend paid (including tax thereon)	4.02		(837.97)		
	NET CASH FROM FINANCING ACTIVITIES		783.51		(284.	
	NET INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS		277.00		(#11	
			266.09		(541.	
	$(\mathbf{A} + \mathbf{B} + \mathbf{C})$					
	(A + B + C) CASH AND CASH EQUIVALENT AS AT THE BEGINNING OF THE PERIOD		184.52		727.	



Notes:-

Place: Mumbai

Dated: November 06, 2020

1. The results of the quarter and half year ended September 30, 2020 were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on November 06, 2020.

2. Other Financial indicators

(Rs. in Lakhs)

Particulars	3 months ended 30/09/2020	3 months ended 30/06/2020	3 months ended 30/09/2019	6 months ended 30/09/2020	6 months ended 30/09/2019	12 months ended 31/03/2020
EBITDA	1,409.73	2,648.00	541.29	4,057.74	1,438.79	2,698.04
% of EBITDA Margin	12.56	21.31	7.30	17.16	9.05	8.79
EBITDA (Adjusted to Forex (gain) / loss and Mark to Market (gain) / loss on Investment in Mutual funds)	1,530.02	2,736.53	764.24	4,266.56	1,661.73	3,433.10
% of Adjusted EBITDA Margin	13.63	22.02	10.31	18.04	10.45	11.18

- 3. On September 22, 2020, the Company passed a circular resolution for allotment of 2,50,56,000 Equity Shares of Rs. 5/- each as fully paid-up Bonus Equity Shares in the ratio of 1:1 to all registered shareholders as on the record date. Consequently, in accordance with Ind AS 33 "Earnings per Share", the basic and diluted earnings per share for all the periods presented above have been adjusted to give effect to the aforesaid issue of Bonus Shares,
- 4. Pursuant to the Taxation Laws (Amendment) Act, 2019, corporate assesses have been given the option under section 115BBA of the Income Tax Act, 1961 to apply lower income tax rate with effect from April, 01, 2019, subject to certain conditions specified therein. The Company had assessed the impact of the Ordinance believes that it will continue to remain in the existing tax structure. Accordingly, no effect in this regards has been considered in measurement of tax expenses for the quarter and period ended September 30, 2020. Management, however will continue to review its profitability forecast at regular intervals and make necessary adjustments to tax expenses when there is reasonable certainty to avail the benefical (lower) rate of tax.
- 5. The Company has identified Bulk drug and Chemicals as its only primary reportable segment in accordance with the requirements of Ind AS 108, 'Operating' Segments'. Accordingly, no-separate segment information has been provided.

6. Previous period's figures have been regrouped and reclassified, wherever necessary, to correspond with those of the current period.

For Anuh Pharma Ltd.

pnishal

Bipin Shah **Managing Director**

(DIN: 00083244)

JAYANTILAL THAKKAR & CO. CHARTERED ACCOUNTANTS

111 (A), MAHATMA GANDHI ROAD, FORT, MUMBAI - 400 023.

TELEPHONES :2265 8800 2265 8900

FAX: (91 - 22) 2265 8989 E-MAIL: jtee @want.net

jtco23@jtco.co.in

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

TO THE BOARD OF DIRECTORS Anuh Pharma Limited

- 1. We have reviewed the accompanying statement of unaudited financial results of Anuh Pharma Limited (the "Company") for the quarter ended 30th September , 2020 and year to date from 1st April,2020 to 30th September,2020 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
- 2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of Interim financial Information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

CHARTERED ACCOUNTANTS

For JAYANTILAL THAKKAR & CO. CHARTERED ACCOUNTANTS (FIRM REG. NO. 104133W)

PLACE: Mumbai DATE: 6th November, 2020.

VIRAL A. MERCHANT PARTNER MEMBERSHIP NO.116279

UDIN: 20116279AAAADA8510

merchant